jerry, I've seen so many retrenchments in the past 4 years after a "good news rally" that I expect the same here. But if the FDA does lift the dosing limitation, then the stock should really move as Cortex will probably subsequently consummate a big BP licensing deal for CX-717.
I think you're trying to catch a falling knife by buying here.
R&R's price target of $4.50 is a joke -- they're the same guys who had a $12 price target not too long ago.
I don't see any logic for the price to advance from here at this time. But, because of past experience, I do see reason to believe the stock will trend lower.
JMO
Market Data 
Markets 
AI
